ATE511843T1 - Dihydropyridin-verbindungen für neurodegenerative erkrankungen und demenz - Google Patents

Dihydropyridin-verbindungen für neurodegenerative erkrankungen und demenz

Info

Publication number: ATE511843T1
Authority: AT; Austria
Prior art keywords: therapeutically effective; effective amounts; disease; dementia; dihydropyridine compounds
Prior art date: 2005-04-04

Application number

AT06740387T

Other languages

English (en)

Inventor

Julian Gray

Yamanishi Yoshiharu

Mori Nobuyuki

Scott Fields

Original Assignee

Eisai R&D Man Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-04-04

Filing date

2006-04-04

Publication date

2011-06-15

2006-04-04 Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd

2011-06-15 Application granted granted Critical

2011-06-15 Publication of ATE511843T1 publication Critical patent/ATE511843T1/de

Links

208000015122 neurodegenerative disease Diseases 0.000 title abstract 3
206010012289 Dementia Diseases 0.000 title abstract 2
YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical class C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 title 1
MMWRGWQTAMNAFC-UHFFFAOYSA-N 1,2-Dihydropyridine Natural products C1NC=CC=C1 MMWRGWQTAMNAFC-UHFFFAOYSA-N 0.000 abstract 3
-1 1,2-dihydropyridine compounds Chemical class 0.000 abstract 3
239000000544 cholinesterase inhibitor Substances 0.000 abstract 3
229940098747 AMPA receptor antagonist Drugs 0.000 abstract 2
239000000775 AMPA receptor antagonist Substances 0.000 abstract 2
ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 abstract 2
239000002664 nootropic agent Substances 0.000 abstract 2
230000001777 nootropic effect Effects 0.000 abstract 2
208000024827 Alzheimer disease Diseases 0.000 abstract 1
229940122041 Cholinesterase inhibitor Drugs 0.000 abstract 1
208000028698 Cognitive impairment Diseases 0.000 abstract 1
208000023105 Huntington disease Diseases 0.000 abstract 1
208000018737 Parkinson disease Diseases 0.000 abstract 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
208000010877 cognitive disease Diseases 0.000 abstract 1
229960003530 donepezil Drugs 0.000 abstract 1
230000004770 neurodegeneration Effects 0.000 abstract 1
PRMWGUBFXWROHD-UHFFFAOYSA-N perampanel Chemical compound O=C1C(C=2C(=CC=CC=2)C#N)=CC(C=2N=CC=CC=2)=CN1C1=CC=CC=C1 PRMWGUBFXWROHD-UHFFFAOYSA-N 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pyridine Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT06740387T 2005-04-04 2006-04-04 Dihydropyridin-verbindungen für neurodegenerative erkrankungen und demenz ATE511843T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US66766505P	2005-04-04	2005-04-04
US68951905P	2005-06-13	2005-06-13
PCT/US2006/012284 WO2006107859A2 (en)	2005-04-04	2006-04-04	Dihydropyridine compounds for neurodegenerative diseases and dementia

Publications (1)

Publication Number	Publication Date
ATE511843T1 true ATE511843T1 (de)	2011-06-15

Family

ID=37074003

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT06740387T ATE511843T1 (de)	2005-04-04	2006-04-04	Dihydropyridin-verbindungen für neurodegenerative erkrankungen und demenz

Country Status (16)

Country	Link
US (3)	US20060270709A1 (de)
EP (2)	EP1871368B1 (de)
JP (2)	JP5180816B2 (de)
KR (1)	KR20080007233A (de)
AT (1)	ATE511843T1 (de)
AU (1)	AU2006232517A1 (de)
CA (1)	CA2603258A1 (de)
CY (1)	CY1112427T1 (de)
DK (1)	DK1871368T3 (de)
HR (1)	HRP20110524T1 (de)
IL (1)	IL186412A0 (de)
ME (1)	ME01224B (de)
PL (1)	PL1871368T3 (de)
PT (1)	PT1871368E (de)
RS (1)	RS51822B (de)
WO (2)	WO2006107860A2 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4614884B2 (ja) *	2003-11-14	2011-01-19	シャンハイゲノミックスインク	ピリドンの誘導体とその使用
US20060270709A1 (en) *	2005-04-04	2006-11-30	Eisai Co. Ltd.	Dihydropyridine compounds and compositions for headaches
AU2006234627C1 (en) *	2005-04-08	2009-11-26	Eisai R & D Management Co., Ltd.	Therapeutic agent for dyskinesia
ES2524922T3 (es)	2005-05-10	2014-12-15	Intermune, Inc.	Derivados de piridona para modular el sistema de proteína cinasa activada por estrés
US7718807B2 (en)	2006-04-28	2010-05-18	Eisai R&D Management Co., Ltd.	Salt of 1,2-dihydropyridine compound
AU2007309390A1 (en) *	2006-10-27	2008-05-02	Medivation Neurology, Inc.	Methods and combination therapies for treating Alzheimer's disease
AU2008210455A1 (en) *	2007-01-31	2008-08-07	Vertex Pharmaceuticals Incorporated	2-aminopyridine derivatives useful as kinase inhibitors
US20100099714A1 (en) *	2007-03-05	2010-04-22	Eisai R&D Management Co., Ltd.	AMPA and NMDA Receptor Antagonists for Neurodegenerative Diseases
WO2009011412A2 (en) *	2007-07-13	2009-01-22	Eisai R & D Management Co., Ltd.	Combination of ampa receptor antagonists and acetylcholinesterase inhibitors for the treatment of neuropathic pain
WO2009054543A1 (en) *	2007-10-26	2009-04-30	Eisai R & D Management Co., Ltd.	Ampa receptor antagonists and zonisamide for parkinson's disease and movement disorders
US20100297181A1 (en) *	2007-12-26	2010-11-25	Eisai R&D Management Co., Ltd.	AMPA Receptor Antagonists for Epilepsy, Mental Disorders or Deficits in Sensory Organ
US20090221554A1 (en) *	2008-02-28	2009-09-03	Zenyaku Kogyo Kabushiki Kaisha	Method of treating cognitive impairment
US8987245B2 (en)	2008-04-02	2015-03-24	Jonathan R. Brestoff Parker	Composition and method for affecting obesity and related conditions
US8598150B1 (en)	2008-04-02	2013-12-03	Jonathan R. Brestoff	Composition and method for affecting obesity and related conditions
CA2726588C (en)	2008-06-03	2019-04-16	Karl Kossen	Compounds and methods for treating inflammatory and fibrotic disorders
ES2402087T3 (es)	2008-07-23	2013-04-26	Vertex Pharmaceuticals Incorporated	Inhibidores de la pirazolopiridina quinasa
US8569337B2 (en)	2008-07-23	2013-10-29	Vertex Pharmaceuticals Incorporated	Tri-cyclic pyrazolopyridine kinase inhibitors
AU2009274023A1 (en)	2008-07-23	2010-01-28	Vertex Pharmaceuticals Incorporated	Tri-cyclic pyrazolopyridine kinase inhibitors
MX2011001319A (es) *	2008-08-06	2011-04-05	Vertex Pharma	Inhibidores de aminopiridina cinasa.
CN102264701A (zh)	2008-12-23	2011-11-30	霍夫曼-拉罗奇有限公司	作为p2x7调节剂的二氢吡啶酮脲
CN102264722B (zh)	2008-12-23	2014-04-02	霍夫曼-拉罗奇有限公司	作为p2x7调节剂的二氢吡啶酮酰胺
AU2009331667A1 (en)	2008-12-23	2010-07-01	F. Hoffmann-La Roche Ag	Dihydropyridone amides as P2X7 modulators
US8153808B2 (en)	2008-12-23	2012-04-10	Roche Palo Alto Llc	Dihydropyridone amides as P2X7 modulators
BRPI0923498A2 (pt)	2008-12-23	2019-09-24	Hoffmann La Roche	amidos de diidropiridona como moduladores de p2x7
CA2760705A1 (en)	2009-05-06	2010-11-11	Vertex Pharmaceuticals Incorporated	Pyrazolopyridines
WO2011094288A1 (en)	2010-01-27	2011-08-04	Vertex Pharmaceuticals Incorporated	Pyrazolopyrazine kinase inhibitors
EP2528917B1 (de)	2010-01-27	2016-10-19	Vertex Pharmaceuticals Incorporated	Zur behandlung von autoimmun-, entzündlichen oder (hyper)proliferativen erkrankungen geeignete pyrazolopyridine
MX2012008643A (es)	2010-01-27	2013-02-26	Vertex Pharma	Inhibidores de cinasas de pirazolopiridinas.
JO2998B1 (ar)	2010-06-04	2016-09-05	Amgen Inc	مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
MX352672B (es)	2011-09-27	2017-12-04	Amgen Inc	Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer.
DK2849781T3 (en)	2012-03-12	2017-10-16	William J Binder	TREATMENT OF MIGRINE HEAD PAIN WITH PRESYNAPTIC NEUROTOXIN
US8722060B2 (en) *	2012-05-23	2014-05-13	William J. Binder	Method of treating vertigo
AR092742A1 (es)	2012-10-02	2015-04-29	Intermune Inc	Piridinonas antifibroticas
TW201441193A (zh)	2012-12-06	2014-11-01	Kyowa Hakko Kirin Co Ltd	吡啶酮化合物
US11407721B2 (en)	2013-02-19	2022-08-09	Amgen Inc.	CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
CA2902856C (en)	2013-02-28	2021-02-16	Amgen Inc.	A benzoic acid derivative mdm2 inhibitor for the treatment of cancer
AU2014236812B2 (en)	2013-03-14	2018-03-01	Amgen Inc.	Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer
CN105358530A (zh)	2013-06-10	2016-02-24	美国安进公司	制备mdm2抑制剂的方法及其结晶形式
MX382781B (es)	2014-04-02	2025-03-13	Intermune Inc	Piridinonas anti-fibroticas.
ES2905564T3 (es)	2014-12-22	2022-04-11	Us Health	Inhibidores mutantes de IDH1 útiles para tratar el cáncer
CN118806909A (zh) *	2016-04-26	2024-10-22	H.隆德贝克有限公司	乙酰胆碱酯酶抑制剂和艾达鲁吡啶用于减少帕金森氏病患者跌倒的用途
US11364225B2 (en) *	2019-08-21	2022-06-21	Bn Intellectual Properties, Inc.	Pharmaceutical formulation for treating symptoms of migraine and cluster headaches, and method of using the same
JPWO2023042887A1 (de) *	2021-09-15	2023-03-23
US20250281474A1 (en) *	2021-09-15	2025-09-11	University Of The Ryukyus	Pharmaceutical composition for treating cognitive decline or for treating overweightness or obesity
IL316768A (en)	2022-05-25	2025-01-01	Ikena Oncology Inc	MEK inhibitors and their uses

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FI95572C (fi) *	1987-06-22	1996-02-26	Eisai Co Ltd	Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
US5262165A (en)	1992-02-04	1993-11-16	Schering Corporation	Transdermal nitroglycerin patch with penetration enhancers
JP3075566B2 (ja)	1990-05-15	2000-08-14	エーザイ株式会社	光学活性インダノン誘導体
JP2965675B2 (ja)	1990-11-21	1999-10-18	エーザイ株式会社	（―）―１―ベンジル―４―〔（５，６―ジメトキシ―１―インダノン）―２―イル〕メチルピペリジンの製造方法
US6010715A (en)	1992-04-01	2000-01-04	Bertek, Inc.	Transdermal patch incorporating a polymer film incorporated with an active agent
US5843945A (en)	1993-05-13	1998-12-01	Neurosearch A/S	AMPA antagonists and a method of treatment
DE4428835A1 (de) *	1994-08-01	1996-02-08	Schering Ag	Neue 3-substituierte 3H-2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel
HU223945B1 (hu) *	1994-09-27	2005-03-29	Yamanouchi Pharmaceutical Co., Ltd.	1,2,3,4-Tetrahidro-kinoxalin-dion-származékok és ezeket tartalmazó gyógyszerkészítmények
CA2222133C (en)	1995-06-07	2002-12-24	Cygnus, Inc.	Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen
AU1153097A (en) *	1996-06-07	1998-01-05	Eisai Co. Ltd.	Stable polymorphs of donepezil (1-benzyl-4-{(5,6-dimethoxy-1-indanon)-2-yl}methylpiperidine ) hydrochloride and process for production
TW513409B (en) *	1996-06-07	2002-12-11	Eisai Co Ltd	Polymorphs of donepezil hydrochloride
CZ141399A3 (cs) *	1996-10-24	1999-07-14	Novartis Ag	Substituované aminoalkanfosfonové kyseliny, způsob jejich přípravy a farmaceutické prostředky, které je obsahují
EP0971713B1 (de) *	1997-03-03	2003-05-28	Eisai Co., Ltd.	Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
US6060479A (en) *	1997-06-09	2000-05-09	Pfizer Inc	Quinazoline-4-one AMPA antagonists
US5948433A (en)	1997-08-21	1999-09-07	Bertek, Inc.	Transdermal patch
US6245911B1 (en) *	1997-12-05	2001-06-12	Eisai Co., Ltd.	Donepezil polycrystals and process for producing the same
JP2002505288A (ja)	1998-03-02	2002-02-19	コセンシス，インコーポレイテッド	置換キナゾリンおよびアナログならびにそれらの使用
IT1304904B1 (it) *	1998-09-11	2001-04-05	Eisai Co Ltd	Derivati anticolinesterasici per il trattamento delle sindromidolorose funzionali e/o organiche
FR2805260A1 (fr) *	2000-02-18	2001-08-24	Adir	Nouveaux derives d'acides 6-sulfamoyl-3-quinolinyl phosphoniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20060183776A9 (en) *	2000-03-03	2006-08-17	Eisai Co., Ltd.	Liquid dosage formulations of donepezil
US20030153598A1 (en) *	2000-07-25	2003-08-14	Raymond Pratt	Methods for treating Parkinson's disease with cholinesterase inhibitors
EP1311272B1 (de) *	2000-03-03	2006-11-22	Eisai Co., Ltd.	Neue methoden unter verwendung von cholinesteraseinhibitoren
WO2001066096A2 (en) *	2000-03-06	2001-09-13	Immune Network Ltd.	Compositions for prevention and treatment of dementia
IL152848A0 (en) *	2000-06-12	2003-06-24	Eisai Co Ltd	1,2-dihydropyridine derivatives, pharmaceutical compositions containing the same and methods for the production thereof
JP2002047272A (ja) *	2000-07-26	2002-02-12	Dai Ichi Seiyaku Co Ltd	ポリアミンアミド誘導体
CA2742411A1 (en) *	2000-09-18	2002-03-21	Eisai R&D Management Co., Ltd.	Pyridazinone and triazinone compounds and use thereof as pharmaceutical preparations
WO2003024456A1 (en) *	2001-09-20	2003-03-27	Eisai Co., Ltd.	Methods for treating and preventing migraines
GB0129260D0 (en) *	2001-12-06	2002-01-23	Eisai London Res Lab Ltd	Pharmaceutical compositions and their uses
WO2004034963A2 (en) *	2002-05-17	2004-04-29	Eisai Co., Ltd.	Methods and compositions using cholinesterase inhibitors
JP4208512B2 (ja) *	2002-07-23	2009-01-14	株式会社クラレ	５−（２’−ピリジル）−２−ピリドン誘導体の製造方法
JP2004189706A (ja) *	2002-12-13	2004-07-08	Eisai Co Ltd	高度アルツハイマー型痴呆治療剤
MY148809A (en) *	2004-07-06	2013-05-31	Eisai R&D Man Co Ltd	Crystals of 1,2-dihydropyridine compound and their production process
US20060270709A1 (en) *	2005-04-04	2006-11-30	Eisai Co. Ltd.	Dihydropyridine compounds and compositions for headaches

2006
- 2006-04-04 US US11/396,555 patent/US20060270709A1/en not_active Abandoned
- 2006-04-04 US US11/887,729 patent/US20090131480A1/en not_active Abandoned
- 2006-04-04 US US11/396,621 patent/US20060276510A1/en not_active Abandoned
- 2006-04-04 DK DK06740387.3T patent/DK1871368T3/da active
- 2006-04-04 AU AU2006232517A patent/AU2006232517A1/en not_active Abandoned
- 2006-04-04 WO PCT/US2006/012285 patent/WO2006107860A2/en not_active Ceased
- 2006-04-04 WO PCT/US2006/012284 patent/WO2006107859A2/en not_active Ceased
- 2006-04-04 AT AT06740387T patent/ATE511843T1/de active
- 2006-04-04 HR HR20110524T patent/HRP20110524T1/hr unknown
- 2006-04-04 PL PL06740387T patent/PL1871368T3/pl unknown
- 2006-04-04 CA CA002603258A patent/CA2603258A1/en not_active Abandoned
- 2006-04-04 PT PT06740387T patent/PT1871368E/pt unknown
- 2006-04-04 RS RS20110318A patent/RS51822B/sr unknown
- 2006-04-04 EP EP06740387A patent/EP1871368B1/de not_active Expired - Lifetime
- 2006-04-04 ME MEP-2011-133A patent/ME01224B/me unknown
- 2006-04-04 KR KR1020077025426A patent/KR20080007233A/ko not_active Ceased
- 2006-04-04 JP JP2008505417A patent/JP5180816B2/ja not_active Expired - Fee Related
- 2006-04-04 JP JP2008505418A patent/JP2008537552A/ja not_active Withdrawn
- 2006-04-04 EP EP06749149A patent/EP1871369A4/de not_active Withdrawn
2007
- 2007-10-07 IL IL186412A patent/IL186412A0/en unknown
2011
- 2011-07-29 CY CY20111101013T patent/CY1112427T1/el unknown

Also Published As

Publication number	Publication date
ME01224B (me)	2013-06-20
EP1871369A4 (de)	2009-11-11
EP1871369A2 (de)	2008-01-02
WO2006107859A2 (en)	2006-10-12
KR20080007233A (ko)	2008-01-17
US20060270709A1 (en)	2006-11-30
JP2008537552A (ja)	2008-09-18
HRP20110524T1 (hr)	2011-08-31
PL1871368T3 (pl)	2011-12-30
IL186412A0 (en)	2008-08-07
PT1871368E (pt)	2011-08-30
WO2006107860A3 (en)	2009-04-09
WO2006107859A8 (en)	2007-11-08
DK1871368T3 (da)	2011-09-19
EP1871368A4 (de)	2009-11-11
RS51822B (sr)	2012-02-29
AU2006232517A1 (en)	2006-10-12
US20060276510A1 (en)	2006-12-07
EP1871368B1 (de)	2011-06-08
WO2006107859A3 (en)	2009-04-09
US20090131480A1 (en)	2009-05-21
EP1871368A2 (de)	2008-01-02
JP5180816B2 (ja)	2013-04-10
CY1112427T1 (el)	2015-12-09
WO2006107860A2 (en)	2006-10-12
CA2603258A1 (en)	2006-10-12
JP2008538216A (ja)	2008-10-16

Legal Events

Date

Code

Title

Description

2012-02-15

UEP

Publication of translation of european patent specification

Ref document number: 1871368

Country of ref document: EP

Publication	Publication Date	Title
ATE511843T1 (de)	2011-06-15	Dihydropyridin-verbindungen für neurodegenerative erkrankungen und demenz
MY148544A (en)	2013-04-30	Pyridyl piperidine orexin receptor antagonists
WO2008111590A3 (en)	2009-02-19	Ampa and nmda receptor antagonists for neurodegenerative diseases
DE60224404D1 (de)	2008-02-14	Substiuierte piperidine als melanocortinrezeptor-modulatoren
WO2009011412A3 (en)	2009-05-07	Combination of ampa receptor antagonists and acetylcholinesterase inhibitors for the treatment of neuropathic pain
TW200621707A (en)	2006-07-01	Substituted dipiperidine CCR2 antagonists cross reference to related applications
MX2007002521A (es)	2007-05-09	Procesos para la preparacion de 2-(2,6-dioxopiperidin-3-il)-1- oxoisoindolinas sustituidas.
MXPA05010496A (es)	2005-11-16	Moduladores alostericos positivos del receptor de acetilcolina nicotinico.
MX2010001486A (es)	2010-03-01	Derivados de tetrahidropiridin carboxamida como antagonistas de trpvl.
MX2009003981A (es)	2009-04-27	Agentes moduladores del receptor de calcio.
NO20092035L (no)	2009-07-15	Tiazolylforbindelser anvendbare som kinaseinhibitorer
NO20060328L (no)	2006-02-17	Kombinasjon av mGluR2-antagonist og ACHE-inhibitor for behandiing av akutt og/eller kronisk neurologiske forstyrrelser
MA28706B1 (fr)	2007-06-01	Antagoniste des recepteurs du glucagon, preparation et utilisations therapeutiques
WO2007056219A3 (en)	2007-12-27	[4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto
NO20073170L (no)	2007-06-22	Kaspaseinhibitorer og anvendelse derav
WO2007079214A3 (en)	2007-08-30	Prokineticin 2 receptor antagonists
TN2009000452A1 (en)	2011-03-31	[4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl] -5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof
EA201001645A1 (ru)	2011-06-30	Хинуклидиновые производные в качестве антагонистов мускаринового м3 рецептора
EA200970553A1 (ru)	2009-10-30	Пиперидиниламинопиридазины и их применение в качестве быстро диссоциирующих антагонистов рецептора допамина 2
MX2009011416A (es)	2009-11-05	Tia(di)azoles como antagonistas del receptor de dopamina 2 de disociacion rapida.
MX2009006528A (es)	2009-06-26	Sal de succinato de la 2-((4-(1-metil-4-(piridin-4-il)-1h-pirazol- 3-il)fenoxi)metil)quinolina.
MX2009000762A (es)	2009-01-28	4-arilalcoximetil-4-fenil piperidinas y su uso como antagonistas del receptor de neuroquinina para el tratamiento de trastornos del sistema nervioso central.
TW200732304A (en)	2007-09-01	Piperidine derivatives
WO2007008514A3 (en)	2007-10-04	Inhibitors of glycogen synthase kinase 3
DE602005012826D1 (de)	2009-04-02	Neue mao-b-hemmer